278.26  5.26 (1.93%)		09-11 16:00
Open: 276.01 High: 280.4 Volume: 767,554		Pre. Close: 273 Low: 275.63 Market Cap: 13,403(M)

Short term
Mid term
Targets	6-month :	335.3	1-year :	354.26
Resists	First :	287.07	Second :	303.3
Pivot price	288.59
Supports	First :	260.82	Second :	217
MAs	MA(5) :	279.77	MA(20) :	287.81
	MA(100) :	219.16	MA(250) :	195.81
MACD	MACD :	5.7	Signal :	10
%K %D	K(14,3) :	11.5	D(3) :	12.7
RSI	RSI(14): 51.2
52-week	High :	303.3	Low :	144.25

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ CRL ] has closed above bottom band by 17.1%. Bollinger Bands are 23.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	281.05 - 282.91	282.91 - 284.6
Low:	270.98 - 273.38	273.38 - 275.55
Close:	274.59 - 278.33	278.33 - 281.72

Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Fri, 11 Sep 2026
Should Automated Test Cartridge Expansion Require Action From Charles River Shares Investors? - simplywall.st

Fri, 11 Sep 2026
Charles River Laboratories International Inc. stock outperforms competitors on strong trading day - MarketWatch

Fri, 11 Sep 2026
Charles River Laboratories to Present at Morgan Stanley and Baird Conferences - ca.finance.yahoo.com

Fri, 11 Sep 2026
Charles River Laboratories to Present at Morgan Stanley and Baird Conferences - Business Wire

Thu, 10 Sep 2026
Charles River Laboratories International Inc. stock outperforms competitors despite losses on the day - MarketWatch

Tue, 08 Sep 2026
Charles River Laboratories International Inc. stock underperforms Tuesday when compared to competitors - MarketWatch

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NYSE
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Shares Out	48 (M)
Shares Float	47 (M)
Held by Insiders	0.4 (%)
Held by Institutions	123.1 (%)
Shares Short	2,360 (K)
Shares Short P.Month	3,340 (K)

EPS	-4.83
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	59.5
Profit Margin	-6 %
Operating Margin	15.1 %
Return on Assets (ttm)	4.1 %
Return on Equity (ttm)	-7.6 %
Qtrly Rev. Growth	-2.8 %
Gross Profit (p.s.)	28.64
Sales Per Share	83.03
EBITDA (p.s.)	17.62
Qtrly Earnings Growth	0 %
Operating Cash Flow	582 (M)
Levered Free Cash Flow	469 (M)

PE Ratio	-57.74
PEG Ratio	0.1
Price to Book value	4.67
Price to Sales	3.35
Price to Cash Flow	23.02

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.